HealthDay News — For patients with mild-to-moderate psoriasis, adherence to topical treatment is low, but an internet-based reporting intervention can improve adherence, according to a study published online September 24 in the British Journal of Dermatology.

Hossein Alinia, from the Wake Forest School of Medicine in Winston-Salem, NC, and colleagues examined how well medication is used in long-term topical treatment of psoriasis in an investigator-blinded prospective study involving 40 patients with mild-to-moderate psoriasis treated with topical fluocinonide over 12 months. Participants were randomized to standard-of-care or an internet-based reporting group in a 1:1 ratio. Medication Event Monitoring System caps were used to measure adherence. 

Related Articles

The researchers found that 50% of participants discontinued treatment. The intervention group had greater adherence than the standard-of-care group (50 versus 35%; P=0.08). Compared with the standard-of-care group, there was more improvement in the Psoriasis Area and Severity Index at month one (1.61 versus 0.12; P=0.003), month three (2.50 versus 0.79; P=0.025), and month 12 (3.32 versus 0.34; P=0.038).

“Adherence to topical treatment is low in short term and decreased further in the long term, a considerable challenge for dermatologists to address,” the authors write. “A reporting intervention may [be] one of the ways we can improve our patients’ treatment outcomes.”

Several authors disclosed financial ties to pharmaceutical companies, including Galderma, which partially funded the research.

Full Text (subscription or payment may be required)